Mounjaro Risks UK - Safety Profile from £124.99

Clinically Proven UK Registered Pharmacy

Mounjaro Risks - Safety Guide from £124.99

Comprehensive safety information from £124.99 with £20 off using code Weightlossnew.

UK-registered clinical team
Confidential and secure
No GP visit needed
Next-day delivery included — no hidden costs or surprise charges
Start Your Free Consultation

Takes less than 2 minutes to complete 100% online

Weightlossnew £20 off for new customers

Treatment from £124.99

Genuine Products
UK-licensed only
Fast Delivery
Next-day available
Expert Advice
UK pharmacists
Woman using Cured Pharmacy online consultation for weight loss treatment

Check your BMI

Height 175 cm
Weight 82 kg

Your BMI

26.8
Start Free Consultation

Free · BMI thresholds shown are illustrative. Final eligibility is confirmed by a UK prescriber during your free consultation.

LIVE PRICING

Our Pricing

Pricing Disclaimer: Prices on some pages may not be up to date — the live pricing table below and pricing shown during consultation are official current prices and take precedence over any other figures on the site.

Mounjaro (Tirzepatide)
Weeks 1–4

2.5mg

1 pen • 4 Weeks

£145 £124.99

£31.25 / Per Week

Your starting dose – designed to help your body adjust gently to treatment

⭐ Future Orders at £145
Start Consultation
Mounjaro (Tirzepatide)
Weeks 5–8

5mg

1 pen • 4 Weeks

£179 £159.00

£39.75 / Per Week

First step up – builds on your progress as your body adapts to treatment

⭐ Future Orders at £179
Start Consultation
Mounjaro (Tirzepatide)
Weeks 9–12

7.5mg

1 pen • 4 Weeks

£220 £200.00

£50.00 / Per Week

Mid-range dose – for continued progression and enhanced results

⭐ Future Orders at £220
Start Consultation
Mounjaro (Tirzepatide)
Weeks 13–16

10mg

1 pen • 4 Weeks

£245 £225.00

£56.25 / Per Week

Higher strength dose – supports significant weight loss progress

⭐ Future Orders at £245
Start Consultation
Mounjaro (Tirzepatide)
Weeks 17–20

12.5mg

1 pen • 4 Weeks

£270 £250.00

£62.50 / Per Week

Advanced dose – for patients requiring stronger therapeutic effect

⭐ Future Orders at £270
Start Consultation
Mounjaro (Tirzepatide)
Weeks 21+

15mg

1 pen • 4 Weeks

£287 £267.00

£66.75 / Per Week

Maximum dose – the highest available strength for optimal results

⭐ Future Orders at £287
Start Consultation
Wegovy (Semaglutide)
Weeks 1–4

0.25mg

1 pen • 4 Weeks

£89 £69.00

£17.25 / Per Week

Your starting dose – eases your body into treatment with minimal side effects

⭐ Future Orders at £89
Start Consultation
Wegovy (Semaglutide)
Weeks 5–8

0.5mg

1 pen • 4 Weeks

£109 £89.00

£22.25 / Per Week

First step up – continues building tolerance for long-term success

⭐ Future Orders at £109
Start Consultation
Wegovy (Semaglutide)
Weeks 9–12

1mg

1 pen • 4 Weeks

£119 £99.00

£24.75 / Per Week

Mid-range dose – where most patients start seeing meaningful results

⭐ Future Orders at £119
Start Consultation
Wegovy (Semaglutide)
Weeks 13–16

1.7mg

1 pen • 4 Weeks

£169 £149.00

£37.25 / Per Week

Higher strength – supports accelerated weight loss progress

⭐ Future Orders at £169
Start Consultation
Wegovy (Semaglutide)
Weeks 17+

2.4mg

1 pen • 4 Weeks

£199 £179.00

£44.75 / Per Week

Maximum dose – the highest available strength for optimal weight management

⭐ Future Orders at £199
Start Consultation
Wegovy (Oral Pill)
Weeks 1–4

1.5mg

1 pen • 4 Weeks

£83.00 £63.00

£20.75 / Per Week

Your starting dose – eases your body into treatment with minimal side effects

⭐ Future Orders at £83.00
Start Consultation
Wegovy (Oral Pill)
Weeks 5–8

4mg

1 pen • 4 Weeks

£110.00 £90.00

£27.50 / Per Week

First step up – continues building tolerance for long-term success

⭐ Future Orders at £110.00
Start Consultation
Wegovy (Oral Pill)
Weeks 9–12

9mg

1 pen • 4 Weeks

£140.00 £120.00

£35.00 / Per Week

Mid-range dose – where most patients start seeing meaningful results

⭐ Future Orders at £140.00
Start Consultation
Wegovy (Oral Pill)
Weeks 13+

25mg

1 pen • 4 Weeks

£199.00 £179.00

£49.75 / Per Week

Maximum dose – the highest available strength for optimal weight management

⭐ Future Orders at £199.00
Start Consultation

Understanding Mounjaro Risks: A Complete UK Safety Guide

Published: 10 September 2026

Understanding mounjaro risks is essential for anyone considering tirzepatide treatment for weight management in the UK. Mounjaro, whilst demonstrating remarkable efficacy in clinical trials with average weight reductions of 15-20% body weight, carries specific side effects and contraindications that require careful clinical assessment by a UK prescriber before initiation. This comprehensive guide examines the evidence-based safety profile, common and serious adverse reactions, and patient-specific risk factors to help you make an informed decision about whether Mounjaro is appropriate for your circumstances.

Common Mounjaro Risks: Gastrointestinal Side Effects

The most frequently reported mounjaro risks involve the gastrointestinal system, affecting up to 80% of patients in the SURPASS clinical trial programme [1]. Nausea represents the most common adverse effect, typically occurring in 15-30% of patients during dose escalation phases. This side effect usually diminishes within 4-8 weeks as the body adapts to tirzepatide's action on GLP-1 and GIP receptors, which slow gastric emptying and enhance satiety signals.

Diarrhoea, vomiting, constipation, and abdominal discomfort constitute additional gastrointestinal mounjaro risks that patients should anticipate [1]. These effects are dose-dependent, meaning they intensify with higher doses (7.5mg, 10mg, 12.5mg, and 15mg) compared to the starting 2.5mg dose. UK prescribers typically recommend gradual dose escalation every four weeks to minimise these adverse reactions, alongside dietary modifications such as smaller, more frequent meals and reduced fat intake.

In clinical practice at Cured Pharmacy, our superintendent pharmacist Tarun Kumar (GPhC 2233073) advises patients to maintain adequate hydration and avoid lying down immediately after meals to reduce reflux symptoms. Whilst these gastrointestinal effects represent the primary mounjaro risks, they rarely necessitate treatment discontinuation when managed appropriately with supportive care and dose adjustments subject to prescriber approval.

Serious Mounjaro Risks: Pancreatitis and Thyroid Concerns

Among the more serious mounjaro risks, acute pancreatitis has been identified in post-marketing surveillance and clinical trials, occurring in approximately 0.2% of patients [2]. Symptoms include severe persistent abdominal pain radiating to the back, nausea, and vomiting. Patients experiencing these symptoms must discontinue Mounjaro immediately and seek urgent medical attention. The MHRA requires healthcare providers to counsel all patients about pancreatitis risk before initiating tirzepatide treatment.

Thyroid C-cell tumours represent another critical consideration when evaluating mounjaro risks, based on rodent studies showing medullary thyroid carcinoma development at high tirzepatide doses [2]. Whilst no causal relationship has been established in humans, Mounjaro carries a boxed warning and is contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). UK prescribers must screen for these conditions during clinical assessment.

Gallbladder Disease and Mounjaro Risks

Cholelithiasis (gallstones) and cholecystitis (gallbladder inflammation) occur more frequently in patients using GLP-1 receptor agonists like Mounjaro, particularly during rapid weight loss phases [3]. The mechanism involves altered bile composition and gallbladder motility. Patients should report symptoms such as right upper quadrant pain, fever, or jaundice to their prescriber promptly, as surgical intervention may be required in severe cases.

Mounjaro Risks for Diabetic Patients: Hypoglycaemia

Hypoglycaemia constitutes a significant concern among mounjaro risks when tirzepatide is used alongside insulin or insulin secretagogues (such as sulphonylureas) in type 2 diabetes management [3]. The SURPASS-2 trial demonstrated hypoglycaemia rates of 0.6% with tirzepatide monotherapy, increasing to 7.3% when combined with basal insulin. Symptoms include tremor, sweating, confusion, palpitations, and in severe cases, loss of consciousness.

UK prescribers typically reduce insulin or sulphonylurea doses by 20-50% when initiating Mounjaro to mitigate hypoglycaemia risk, with further adjustments based on continuous glucose monitoring or self-monitored blood glucose readings [4]. Patients must be educated to recognise hypoglycaemia symptoms and carry rapid-acting carbohydrate sources (glucose tablets, fruit juice) at all times. This represents one of the most manageable mounjaro risks through appropriate dose titration and patient education.

Treatment Type Common Side Effects Starting Price
Mounjaro GLP-1/GIP injection Nausea, diarrhoea, vomiting from £145.00
Wegovy GLP-1 injection Nausea, constipation, fatigue from £89.00
Wegovy Oral Tablets GLP-1 oral tablet Nausea, headache, diarrhoea from £83.00
Saxenda GLP-1 injection Nausea, hypoglycaemia risk from £68.00
Orlistat Lipase inhibitor Oily stools, flatulence from £32.00

Cardiovascular and Renal Mounjaro Risks

Whilst tirzepatide demonstrates cardiovascular benefits in clinical trials, certain mounjaro risks warrant attention in susceptible populations [4]. Tachycardia (increased heart rate) occurs in approximately 5-10% of patients, typically mild and transient. However, patients with pre-existing cardiac arrhythmias or congestive heart failure require closer monitoring during treatment initiation.

Acute kidney injury represents an uncommon but serious adverse effect, usually secondary to severe dehydration from persistent vomiting or diarrhoea [5]. The MHRA advises particular caution in elderly patients and those with baseline renal impairment. UK prescribers should assess renal function before starting Mounjaro and monitor electrolytes in patients experiencing significant gastrointestinal symptoms. These mounjaro risks are substantially reduced through adequate hydration and prompt management of gastrointestinal adverse effects.

Diabetic Retinopathy Complications

Rapid improvement in glycaemic control with Mounjaro may temporarily worsen diabetic retinopathy in patients with pre-existing eye disease [5]. The SURPASS-4 trial identified retinopathy progression in 3% of tirzepatide-treated patients versus 2% in placebo groups. Patients with proliferative diabetic retinopathy or maculopathy should undergo ophthalmological assessment before treatment and receive regular monitoring throughout therapy, representing an important consideration among mounjaro risks for long-standing diabetic patients.

Contraindications and Patient-Specific Mounjaro Risks

Absolute contraindications to Mounjaro include personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, and known hypersensitivity to tirzepatide or excipients [6]. These represent non-negotiable mounjaro risks that preclude treatment initiation. Additionally, pregnancy and breastfeeding constitute contraindications, as tirzepatide's effects on foetal development and infant safety remain unknown. Women of childbearing potential must use reliable contraception and discontinue Mounjaro at least two months before planned conception.

Relative contraindications requiring careful risk-benefit assessment include severe gastroparesis, inflammatory bowel disease, history of pancreatitis, and advanced chronic kidney disease (eGFR <30 mL/min/1.73m²) [6]. Patients over 75 years face increased mounjaro risks due to reduced physiological reserve and polypharmacy interactions. UK prescribers at Cured Pharmacy conduct comprehensive clinical assessments to identify these risk factors before approving treatment, ensuring patient safety remains paramount.

At £124.99 per month from Cured Pharmacy, Mounjaro treatment includes mandatory clinical assessment by UK-registered prescribers who evaluate individual risk profiles against potential benefits. New patients receive £20 off their first order with code Weightlossnew, making evidence-based weight management more accessible whilst maintaining rigorous safety standards through our GPhC-registered pharmacy (9012511).

Managing and Minimising Mounjaro Risks in Clinical Practice

Effective management of mounjaro risks begins with thorough patient selection through comprehensive clinical assessment, including medical history review, medication reconciliation, and baseline laboratory investigations (HbA1c, renal function, lipid profile) [7]. UK prescribers should exclude absolute contraindications and carefully weigh relative contraindications against anticipated benefits, particularly in patients with BMI ≥30 kg/m² or ≥27 kg/m² with weight-related comorbidities.

Dose escalation strategy significantly influences the severity of mounjaro risks, particularly gastrointestinal adverse effects [7]. The licensed UK regimen initiates treatment at 2.5mg weekly for four weeks, increasing to 5mg for four weeks, then 7.5mg, 10mg, 12.5mg, and finally 15mg at four-week intervals. Patients experiencing intolerable side effects may remain at their current dose longer or step back to the previous dose, subject to prescriber guidance. This individualised approach optimises tolerability whilst maintaining therapeutic efficacy.

Patient education represents the cornerstone of risk mitigation, encompassing recognition of serious adverse effects requiring immediate medical attention (severe abdominal pain, persistent vomiting, visual changes), strategies for managing common gastrointestinal symptoms, and the importance of adherence to follow-up schedules [8]. Regular monitoring appointments allow early detection of emerging complications and dose adjustments to minimise mounjaro risks whilst maximising weight loss outcomes. Our clinical team at Cured Pharmacy provides ongoing support throughout treatment, ensuring patients receive expert guidance from UK-registered healthcare professionals.

When to Discontinue Mounjaro Due to Safety Concerns

Immediate discontinuation of Mounjaro is warranted if patients develop signs of pancreatitis, severe allergic reactions (anaphylaxis, angioedema), or acute kidney injury [8]. Persistent severe gastrointestinal symptoms unresponsive to supportive measures, confirmed gallbladder disease requiring intervention, or worsening diabetic retinopathy may also necessitate treatment cessation. These scenarios represent situations where mounjaro risks outweigh potential benefits, requiring transition to alternative weight management strategies under medical supervision.

Scientific References

  1. Rosenstock, J., Wysham, C., Frías, J. P., Kaneko, S., Lee, C. J., Fernández Landó, L., Mao, H., Cui, X., Karanikas, C. A., & Thieu, V. T. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet, 398(10295), 143-155. [accessed 10 September 2026]
  2. Medicines and Healthcare products Regulatory Agency. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen - Summary of Product Characteristics. Electronic Medicines Compendium. [accessed 10 September 2026]
  3. Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., Brown, K. D., SURPASS-2 Investigators. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503-515. [accessed 10 September 2026]
  4. Del Prato, S., Kahn, S. E., Pavo, I., Weerakkody, G. J., Yang, Z., Doupis, J., Aizenberg, D., Wynne, A. G., Riesmeyer, J. S., Heine, R. J., & Wiese, R. J. (2021). Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. The Lancet, 398(10313), 1811-1824. [accessed 10 September 2026]
  5. National Institute for Health and Care Excellence. (2023). Tirzepatide for treating type 2 diabetes. NICE Technology Appraisal Guidance [TA924]. [accessed 10 September 2026]
  6. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., Stefanski, A., & SURMOUNT-1 Investigators. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 10 September 2026]
  7. Garvey, W. T., Frias, J. P., Jastreboff, A. M., le Roux, C. W., Sattar, N., Aizenberg, D., Mao, H., Zhang, S., Ahmad, N. N., Bunck, M. C., Benabbad, I., Zhang, X. M., & SURMOUNT-2 Investigators. (2023). Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. The Lancet, 402(10402), 613-626. [accessed 10 September 2026]
  8. Royal Pharmaceutical Society. (2023). Professional guidance on the safe supply of GLP-1 receptor agonists for weight management. RPS Professional Standards and Guidance. [accessed 10 September 2026]
  9. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 10 September 2026.
  10. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 10 September 2026.
  11. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 10 September 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.

Trusted by thousands

Real people, real results

Jane L.

"Brilliant. Lost 4 stone on mounjaro no side effects at all. Cured pharmacy are excellent. Always helpful pens sent out quickly always comes with needles and sterile wipes. If you want to go on GLP-1 go to cured pharmacy. So professional. Thank you cured pharmacy you changed my health and well being."

Ann-Marie

"I absolutely love this product, I have been using 2.5mg as maintenance dose and have managed to control my weight without any side effects and can still eat well balanced meals. The pharmacy is very efficient friendly and helpful I would not purchase from anywhere else."

Sacha W.

"So far I'm really impressed by my results it's crazy cause I'm not snacking like how I used to do and I see my face slimming down already and it's only been 2 and a half weeks. Can't wait to give my feedback in 5 months time thank you cured pharmacy."

Kimberly G.

"Mounjaro has corrected my hormonal weight gain during menopause. I am using it now to maintain that balance. The results for me have been exceptional!"

Jennifer

"Great really helps cure those nasty habits can't wait for my next mounjaro pen."

How it Works?

Select from our recommended UK-licensed medications.

1

Choose your treatment

Step 1: Choose your treatment from Cured Pharmacy

Select safe UK treatments. Quick answers.

2

Answer quick questions

Step 2: Answer quick consultation questions

We will deliver direct to you as quickly as tomorrow.

3

Get it delivered fast

Step 3: Fast discreet delivery to your door

Start Your Assessment For Weight Loss

Start your journey to better health today.

  • Reviewed by UK-based prescribers
  • Takes under 3 minutes
  • Discreet Packaging

Start Your Journey To Better Health Today

Once you complete a short online assessment you will be able to choose your preferred treatment from safe medically approved options tailored to you.

Start My Assessment

Returning Customer?

Log in to Your Account

Faq

What are the most common mounjaro risks patients experience?
The most common mounjaro risks are gastrointestinal side effects including nausea (15-30% of patients), diarrhoea, vomiting, and constipation, typically occurring during dose escalation and diminishing within 4-8 weeks as the body adapts to treatment.
Are there serious mounjaro risks I should be concerned about?
Serious mounjaro risks include acute pancreatitis (0.2% incidence), potential thyroid C-cell tumours (contraindicated with personal/family history of medullary thyroid carcinoma), gallbladder disease, and acute kidney injury secondary to dehydration. Immediate medical attention is required if severe symptoms develop.
Who should not take Mounjaro due to safety risks?
Mounjaro is contraindicated in patients with personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, pregnancy, breastfeeding, or known hypersensitivity to tirzepatide. Careful assessment is required for those with severe gastroparesis, inflammatory bowel disease, or advanced kidney disease.
How can I minimise mounjaro risks during treatment?
Minimising mounjaro risks involves following the prescribed dose escalation schedule, maintaining adequate hydration, eating smaller frequent meals, reporting severe symptoms promptly to your prescriber, and attending regular monitoring appointments to detect complications early.
Does Mounjaro cause hypoglycaemia?
Mounjaro monotherapy carries low hypoglycaemia risk (0.6% in trials), but this increases significantly when combined with insulin or sulphonylureas. UK prescribers typically reduce doses of these medications by 20-50% when initiating Mounjaro to mitigate this risk.
What are the cardiovascular mounjaro risks?
Cardiovascular mounjaro risks include mild tachycardia (increased heart rate) in 5-10% of patients, typically transient and benign. Patients with pre-existing cardiac arrhythmias or heart failure require closer monitoring, though tirzepatide demonstrates overall cardiovascular benefits in clinical trials.
Can Mounjaro affect my kidneys?
Acute kidney injury is an uncommon but serious mounjaro risk, usually secondary to severe dehydration from persistent vomiting or diarrhoea. UK prescribers assess renal function before treatment and monitor patients experiencing significant gastrointestinal symptoms, particularly elderly patients and those with baseline kidney impairment.
Is Mounjaro safe for long-term use?
Clinical trials demonstrate acceptable safety profiles for tirzepatide use up to 72 weeks, with most mounjaro risks (particularly gastrointestinal effects) diminishing over time. Long-term safety continues to be monitored through post-marketing surveillance by the MHRA, with ongoing patient monitoring recommended throughout treatment duration.
Tarun Kumar, Prescribing Pharmacist

Medically reviewed by

Tarun Kumar, Prescribing Pharmacist (GPhC 2233073)

Last reviewed: 10 September 2026

Last updated on 10 September 2026.

Review History

Our experts continually monitor new findings in health and medicine, and we update our articles when new information becomes available.

Why this page was updated on 10 September 2026

Content checked and updated as part of our periodic review, to ensure accuracy and currentness.

Current version (10 September 2026)

Edited by: The Editorial Team

Medically reviewed by:

Tarun Kumar, GPhC No. 2233073, Prescribing Pharmacist


How we source info.

When we present you with stats, data, opinion or a consensus, we'll tell you where this came from.